Key result
Longer post-procedural length of stay was associated with an increased risk of 30-day all-cause readmission after TAVR and MitraClip.
Why the study?
Post-procedural hospital length of stay is an important determinant of cost-related outcomes, but its impact on short-term outcomes after TAVR and MitraClip needed assessment.
Does longer post-procedural length of stay increase the risk of 30-day all-cause mortality and readmissions in patients undergoing TAVR and MitraClip?
Cohort (n=73,073)
Yes
Does longer post-procedural length of stay increase the risk of 30-day all-cause mortality and readmissions in patients undergoing TAVR and MitraClip?
Longer post-procedural length of stay after TAVR and MitraClip is associated with an increased risk of 30-day readmission, suggesting these patients represent a sicker cohort requiring closer follow-up.
Answers are grounded in this paper and cite their sources.
May warrant closer post-discharge surveillance in TAVR and MitraClip patients with prolonged stays; hypothesis-generating for targeted interventions.
Background: Post-procedural hospital length of stay (P-LOS) is an important determinant of cost-related outcomes. In the present study, we aimed to assess the impact of P-LOS on short-term outcomes after transcatheter aortic valve replacement (TAVR) and MitraClip. Methods: We performed a retrospective cohort study, retrieving data from the National Readmissions Database (NRD) for patients who underwent transfemoral TAVR and MitraClip between January 2014 and December 2017. We employed multivariable logistic regression to evaluate the association between P-LOS and 30-day all-cause mortality and readmissions. Results: A total of 65,726 and 7347 patients underwent TAVR and MitraClip, respectively within the study period. After 30 days of discharge, 13.7% and 15.1% of TAVR and MitraClip patients were readmitted for any reason, while 0.5% and 0.9% died within the readmission hospitalization. A longer P-LOS was associated with an increased risk of 30-day all-cause readmission in both TAVR (OR = 1.027, 95% CI [1.023-1.032]) and MitraClip (OR = 1.025, 95%CI [1.012-1.038]) patients. This finding remained true for patients who developed or did not develop complications after both procedures. In terms of 30-day inhospital mortality, a longer P-LOS was associated with a higher risk in TAVR patients (OR = 1.039, 95%CI [1.028-1.049]), but no increased risk in MitraClip patients (OR = 1.014, 95%CI [0.985-1.044]). Other predictors of 30-day readmission after both procedures included heart failure, post-procedural acute kidney injury, and discharge with disability. Conclusion: The current study shows that shorter P-LOS was associated with reduced risk of short-term readmission after both TAVR and MitraClip and reduced short-term mortality after TAVR (mainly in patients who developed post-procedural complications). Shorter P-LOS is a predictor of readmission and sicker patient group. Patients requiring longer LOS should be followed closely to prevent readmission and enhance better outcomes. Future studies evaluating P-LOS impact on long-term and patient-oriented outcomes are needed.
No takes yet. Share an insight, caveat, or question.
Abdelfattah et al. (2022) conducted a cohort in Patients undergoing transfemoral TAVR or MitraClip (n=73,073). Longer post-procedural length of stay vs. Shorter post-procedural length of stay was evaluated on 30-day all-cause readmission (OR 1.027, 95% CI 1.023-1.032). Longer post-procedural length of stay was associated with an increased risk of 30-day all-cause readmission after TAVR and MitraClip.
Synapse has enriched 10 related papers. Consider them for comparative context: